<DOC>
	<DOCNO>NCT00049998</DOCNO>
	<brief_summary>The purpose study collect information effective well tolerated oral investigational drug compare standard intravenous drug patient pretreated , advance non-small lung cancer ( NSCLC ) .</brief_summary>
	<brief_title>Oral Topotecan Versus Intravenous Docetaxel In Pretreated , Advanced Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Topotecan</mesh_term>
	<criteria>Written inform consent Patients advance nonsmall cell lung cancer ( NSCLC ) . Patients receive one previous chemotherapy NSCLC . Full recovery previous chemotherapy . Presence either measurable nonmeasurable disease radiologic study physical examination . At least 3 week since last major surgery ( less period acceptable deem best interest patient ) . At least 24 hour since prior radiotherapy provide mark bone marrow suppression NOT expect . Patients receive radiotherapy must recover reversible side effect ( e.g . nausea vomit ) . Laboratory criterion : Patients must adequate bone marrow reserve adequate kidney liver function . Symptoms brain metastasis ( cancer spread brain ) , require treatment steroid . Active infection . Severe medical problem diagnosis NSCLC , would limit ability patient follow study guideline expose patient extreme risk . Ongoing plan chemotherapy , immunotherapy , radiotherapy , investigational therapy treatment NSCLC . Use investigational drug within 30 day prior first dose study medication . Women pregnant lactating . Patients childbearing potential refusing practice adequate birth control method . Patients condition might alter absorption oral drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>Nonsmall Cell Lung cancer</keyword>
	<keyword>advanced</keyword>
	<keyword>Second-line</keyword>
	<keyword>topotecan</keyword>
	<keyword>Hycamtin</keyword>
	<keyword>oral</keyword>
	<keyword>docetaxel</keyword>
</DOC>